182 related articles for article (PubMed ID: 38232613)
1. Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b.
Seon BK; Okazaki M; Duzen J; Matsuno F; Goey AKL; Maguire O
Leuk Res; 2024 Jan; 136():107436. PubMed ID: 38232613
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.
Huse K; Bai B; Hilden VI; Bollum LK; Våtsveen TK; Munthe LA; Smeland EB; Irish JM; Wälchli S; Myklebust JH
J Immunol; 2022 Nov; 209(10):2042-2053. PubMed ID: 36426942
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterisation of the CD79a and CD79b subunits of the B cell receptor complex in the gray short-tailed opossum (Monodelphis domestica) and tammar wallaby (Macropus eugenii): Delayed B cell immunocompetence in marsupial neonates.
Duncan L; Webster K; Gupta V; Nair S; Deane E
Vet Immunol Immunopathol; 2010 Aug; 136(3-4):235-47. PubMed ID: 20399507
[TBL] [Abstract][Full Text] [Related]
4. B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.
Tkachenko A; Kupcova K; Havranek O
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203179
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.
Astsaturov IA; Matutes E; Morilla R; Seon BK; Mason DY; Farahat N; Catovsky D
Leukemia; 1996 May; 10(5):769-73. PubMed ID: 8656670
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Polson AG; Yu SF; Elkins K; Zheng B; Clark S; Ingle GS; Slaga DS; Giere L; Du C; Tan C; Hongo JA; Gogineni A; Cole MJ; Vandlen R; Stephan JP; Young J; Chang W; Scales SJ; Ross S; Eaton D; Ebens A
Blood; 2007 Jul; 110(2):616-23. PubMed ID: 17374736
[TBL] [Abstract][Full Text] [Related]
7. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
8. CD79: a review.
Chu PG; Arber DA
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):97-106. PubMed ID: 11396639
[TBL] [Abstract][Full Text] [Related]
9. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
Pfeifer M; Zheng B; Erdmann T; Koeppen H; McCord R; Grau M; Staiger A; Chai A; Sandmann T; Madle H; Dörken B; Chu YW; Chen AI; Lebovic D; Salles GA; Czuczman MS; Palanca-Wessels MC; Press OW; Advani R; Morschhauser F; Cheson BD; Lenz P; Ott G; Polson AG; Mundt KE; Lenz G
Leukemia; 2015 Jul; 29(7):1578-86. PubMed ID: 25708834
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Analysis of Candidate Anti-Human CD79 Therapeutic Antibodies Using a Humanized CD79 Mouse Model.
Wemlinger SM; Parker Harp CR; Yu B; Hardy IR; Seefeldt M; Matsuda J; Mingueneau M; Spilker KA; Cameron TO; Larrick JW; Getahun A; Cambier JC
J Immunol; 2022 Apr; 208(7):1566-1584. PubMed ID: 35321883
[TBL] [Abstract][Full Text] [Related]
12. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
[TBL] [Abstract][Full Text] [Related]
13. Isoforms of the CD79 signal transduction component of the macropod B-cell receptor.
Suthers AN; Young LJ
Dev Comp Immunol; 2014 Dec; 47(2):185-90. PubMed ID: 25064685
[TBL] [Abstract][Full Text] [Related]
14. B cell receptor accessory molecule CD79 gets involved in response against Streptococcus agalactiae infection and BCR signaling in Nile tilapia (Oreochromis niloticus).
Wu L; Bian X; Kong L; Yin X; Mu L; Wu S; Gao A; Wei X; Guo Z; Ye J
Fish Shellfish Immunol; 2019 Apr; 87():212-219. PubMed ID: 30648625
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
[TBL] [Abstract][Full Text] [Related]
16. Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal transduction.
Pao LI; Famiglietti SJ; Cambier JC
J Immunol; 1998 Apr; 160(7):3305-14. PubMed ID: 9531288
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing of CD79a (Ig-alpha/mb-1) and CD79b (Ig-beta/B29) RNA transcripts in human B cells.
Hashimoto S; Chiorazzi N; Gregersen PK
Mol Immunol; 1995 Jun; 32(9):651-9. PubMed ID: 7643857
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning and expression analysis of CD79a and CD79b in rainbow trout (Oncorhynchus mykiss) after bacterial, parasitic, and viral infection.
Cheng GF; Kong WG; Zhai X; Mu QJ; Dong ZR; Zhan MT; Xu Z
Fish Shellfish Immunol; 2021 Nov; 118():385-395. PubMed ID: 34563671
[TBL] [Abstract][Full Text] [Related]
19. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
